Comparative Pharmacology
Head-to-head clinical analysis: KENALOG 80 versus SYNALAR HP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KENALOG 80 versus SYNALAR HP.
KENALOG-80 vs SYNALAR-HP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Triamcinolone acetonide is a synthetic corticosteroid with potent anti-inflammatory, immunosuppressive, and anti-proliferative effects. It binds to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of phospholipase A2, which reduces prostaglandin and leukotriene synthesis. It also suppresses cytokine production and immune cell migration.
Corticosteroid that binds to glucocorticoid receptors, altering gene expression to inhibit inflammatory mediators (e.g., prostaglandins, leukotrienes) and suppress immune cell activity.
60 mg (1.5 mL) intramuscularly (deep IM) as a single dose for allergic/ inflammatory conditions; intra-articular or soft tissue injection: 10-40 mg for large joints, 5-25 mg for medium joints, 2.5-10 mg for small joints; intralesional: up to 1 mg per injection site, repeated as needed.
Apply a thin film to the affected area once or twice daily for up to 2 weeks, using the lowest effective dose. Not for use under occlusive dressings or on large areas.
None Documented
None Documented
Terminal elimination half-life: 2–4 hours for triamcinolone acetonide; prolonged in hepatic impairment (up to 6–8 hours).
Terminal half-life: 2-3 hours (topical) due to rapid clearance; systemic half-life: 1-2 hours
Primarily hepatic metabolism followed by renal excretion of inactive metabolites; less than 5% excreted unchanged in urine, with minor biliary/fecal elimination (<2%).
Renal: 90% as metabolites; biliary/fecal: minimal (<5%)
Category C
Category C
Corticosteroid
Corticosteroid